Entrada Therapeutics Q1 Revenue $875K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy TRDA?
Reports Q1 revenue $875,000, consensus $2.92M. "With the recently announced positive data from Cohort 1 of our ELEVATE-44-201 clinical study, this year has already delivered a significant clinical inflection point. Establishing that ENTR-601-44 demonstrated not only favorable safety and tolerability, but early and differentiated functional benefits at 6 mg/kg, is a clear milestone for the program as well as Entrada's neuromuscular pipeline," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "With cash runway into the third quarter of 2027, we are well positioned to achieve additional clinical inflection points throughout the year, including data from the first participant cohort of the ELEVATE-45-201 study, as well as the open-label and second cohort of the ELEVATE-44-201 study. The Company is also carefully evaluating the optimal timing for initiating the planned clinical studies of ENTR-601-50 and ENTR-601-51."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRDA
Wall Street analysts forecast TRDA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.850
Low
13.00
Averages
16.50
High
20.00
Current: 6.850
Low
13.00
Averages
16.50
High
20.00
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entrada Therapeutics Shares Plunge 55% Following Trial Data Release
- Trial Data Reaction: Entrada Therapeutics reported a statistically significant 0.115 mean change in Time to Rise velocity for ENTR-601-44 in the ELEVATE-44-201 trial compared to placebo; however, this result failed to impress Wall Street, leading to a ~55% drop in shares to a five-month low.
- Participant Details: The trial included eight patients aged 6 to 17 with Duchenne muscular dystrophy, enrolled in Cohort 1 of the multiple ascending dose portion, targeting patients aged 4 to 20 whose DMD gene is amenable to the 'exon 44 skipping' treatment mechanism.
- Safety Assessment: Entrada indicated a favorable tolerability profile for the intravenous therapy, noting no serious adverse events or events leading to trial discontinuations, with all eight subjects progressing to the open-label phase of the study.
- Future Outlook: The company expects to report data from the open-label portion of ELEVATE-44-201 and the Cohort 2 MAD portion by the end of this year, demonstrating its ongoing commitment to advancing research.
See More
Entrada Therapeutics to Announce Phase 1/2 ELEVATE-44-201 Results
- Clinical Trial Results Announcement: Entrada Therapeutics is set to release topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study on May 7, 2026, which is expected to provide critical data support for the company's future drug development.
- Investor Webcast: The company will host an investor webcast at 8:30 a.m. ET to discuss the clinical results, enhancing investor understanding and confidence in the company's R&D progress.
- Novel Genetic Medicine Development: Entrada focuses on developing genetic medicines targeting neuromuscular and inherited retinal diseases, aiming to provide treatment options for intracellular targets long considered inaccessible, presenting significant market potential.
- Collaborative Project Advancement: The partnership on the VX-670 program for myotonic dystrophy type 1 further expands Entrada's influence and market opportunities in the gene therapy sector.
See More
Entrada Therapeutics Grants Restricted Stock Units to New Employees
- Employee Incentive Plan: Entrada Therapeutics granted a total of 12,990 restricted stock units (RSUs) to two newly hired non-executive employees under its 2025 Inducement Equity Plan, aimed at attracting talent and complying with Nasdaq listing rules.
- Grant Details: The RSUs will vest 25% on the one-year anniversary of the grant date, with 6.25% vesting quarterly thereafter, ensuring employees remain with the company to realize their benefits, thereby enhancing retention.
- Strategic Focus: Entrada is dedicated to developing genetic medicines for neuromuscular and inherited retinal diseases, aiming to transform patient lives through innovative gene therapies, reflecting the company's forward-looking strategy in the biopharmaceutical sector.
- Clinical Program Advancements: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and collaborating on a clinical-stage program for myotonic dystrophy type 1, showcasing its potential in treating rare diseases.
See More
Entrada Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Entrada Therapeutics reported a Q4 GAAP EPS of -$0.94, beating expectations by $0.30, indicating efforts in loss control; however, the revenue of $1.3 million, down 96.5% year-over-year, fell short of expectations, highlighting significant challenges in the business.
- Revenue Shortfall: Despite the improvement in EPS, the revenue of $1.3 million was substantially below the expected $6.11 million, reflecting considerable difficulties in market competition and product sales, which may impact future investor confidence.
- Cash Position: As of December 31, 2025, Entrada holds $296 million in cash, cash equivalents, and marketable securities, with a cash runway expected to last into Q3 2027, providing a financial buffer but necessitating improvements in revenue generation.
- Future Outlook: Although current financial performance is poor, Entrada Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference to seek potential partnerships and investor support, aiming for business recovery and growth in the future.
See More
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be live-streamed on Entrada's Investor Relations website and will be archived for 30 days post-event, ensuring that investors who cannot attend in real-time can access key information, thereby enhancing the company's transparency.
- Company Background: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™) therapeutics that enable efficient delivery of treatments, aiming to improve therapeutic indices and provide potential solutions for neuromuscular and ocular diseases, highlighting its strategic positioning in innovative drug development.
- R&D Project Progress: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and is collaborating on a clinical-stage program, VX-670, for myotonic dystrophy type 1, indicating its deep commitment and market potential in specific disease areas.
See More
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
- Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
- Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
See More
Entrada Therapeutics Shares Plunge 55% Following Trial Data Release
- Trial Data Reaction: Entrada Therapeutics reported a statistically significant 0.115 mean change in Time to Rise velocity for ENTR-601-44 in the ELEVATE-44-201 trial compared to placebo; however, this result failed to impress Wall Street, leading to a ~55% drop in shares to a five-month low.
- Participant Details: The trial included eight patients aged 6 to 17 with Duchenne muscular dystrophy, enrolled in Cohort 1 of the multiple ascending dose portion, targeting patients aged 4 to 20 whose DMD gene is amenable to the 'exon 44 skipping' treatment mechanism.
- Safety Assessment: Entrada indicated a favorable tolerability profile for the intravenous therapy, noting no serious adverse events or events leading to trial discontinuations, with all eight subjects progressing to the open-label phase of the study.
- Future Outlook: The company expects to report data from the open-label portion of ELEVATE-44-201 and the Cohort 2 MAD portion by the end of this year, demonstrating its ongoing commitment to advancing research.
See More
Entrada Therapeutics to Announce Phase 1/2 ELEVATE-44-201 Results
- Clinical Trial Results Announcement: Entrada Therapeutics is set to release topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study on May 7, 2026, which is expected to provide critical data support for the company's future drug development.
- Investor Webcast: The company will host an investor webcast at 8:30 a.m. ET to discuss the clinical results, enhancing investor understanding and confidence in the company's R&D progress.
- Novel Genetic Medicine Development: Entrada focuses on developing genetic medicines targeting neuromuscular and inherited retinal diseases, aiming to provide treatment options for intracellular targets long considered inaccessible, presenting significant market potential.
- Collaborative Project Advancement: The partnership on the VX-670 program for myotonic dystrophy type 1 further expands Entrada's influence and market opportunities in the gene therapy sector.
See More
Entrada Therapeutics Grants Restricted Stock Units to New Employees
- Employee Incentive Plan: Entrada Therapeutics granted a total of 12,990 restricted stock units (RSUs) to two newly hired non-executive employees under its 2025 Inducement Equity Plan, aimed at attracting talent and complying with Nasdaq listing rules.
- Grant Details: The RSUs will vest 25% on the one-year anniversary of the grant date, with 6.25% vesting quarterly thereafter, ensuring employees remain with the company to realize their benefits, thereby enhancing retention.
- Strategic Focus: Entrada is dedicated to developing genetic medicines for neuromuscular and inherited retinal diseases, aiming to transform patient lives through innovative gene therapies, reflecting the company's forward-looking strategy in the biopharmaceutical sector.
- Clinical Program Advancements: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and collaborating on a clinical-stage program for myotonic dystrophy type 1, showcasing its potential in treating rare diseases.
See More
Entrada Therapeutics Q4 Earnings Report Analysis
- Earnings Performance: Entrada Therapeutics reported a Q4 GAAP EPS of -$0.94, beating expectations by $0.30, indicating efforts in loss control; however, the revenue of $1.3 million, down 96.5% year-over-year, fell short of expectations, highlighting significant challenges in the business.
- Revenue Shortfall: Despite the improvement in EPS, the revenue of $1.3 million was substantially below the expected $6.11 million, reflecting considerable difficulties in market competition and product sales, which may impact future investor confidence.
- Cash Position: As of December 31, 2025, Entrada holds $296 million in cash, cash equivalents, and marketable securities, with a cash runway expected to last into Q3 2027, providing a financial buffer but necessitating improvements in revenue generation.
- Future Outlook: Although current financial performance is poor, Entrada Therapeutics is actively participating in the 44th Annual J.P. Morgan Healthcare Conference to seek potential partnerships and investor support, aiming for business recovery and growth in the future.
See More
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor and industry attention.
- Webcast Availability: The presentation will be live-streamed on Entrada's Investor Relations website and will be archived for 30 days post-event, ensuring that investors who cannot attend in real-time can access key information, thereby enhancing the company's transparency.
- Company Background: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing Endosomal Escape Vehicle (EEV™) therapeutics that enable efficient delivery of treatments, aiming to improve therapeutic indices and provide potential solutions for neuromuscular and ocular diseases, highlighting its strategic positioning in innovative drug development.
- R&D Project Progress: The company is advancing its lead oligonucleotide programs for Duchenne muscular dystrophy and is collaborating on a clinical-stage program, VX-670, for myotonic dystrophy type 1, indicating its deep commitment and market potential in specific disease areas.
See More
Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference
- Conference Presentation: Entrada Therapeutics CEO Dipal Doshi will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast: The presentation will be available via live webcast on Entrada's Investor Relations website, with a replay accessible for 30 days post-event, aimed at increasing engagement and transparency with potential investors.
- Company Overview: Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuromuscular and ocular diseases, showcasing its cutting-edge position in the biopharmaceutical sector.
- Product Development: The company is advancing a robust portfolio of RNA and protein-based programs, particularly targeting treatments for Duchenne muscular dystrophy, indicating its potential in addressing challenging diseases.
See More
